Nurix Therapeutics Inc (NAS:NRIX)
$ 15.9 0.95 (6.35%) Market Cap: 970.97 Mil Enterprise Value: 698.12 Mil PE Ratio: 0 PB Ratio: 4.35 GF Score: 67/100

Nurix Therapeutics Inc at Wells Fargo Healthcare Conference Transcript

Sep 07, 2022 / 07:45PM GMT
Release Date Price: $16.12 (+5.36%)
Derek Archila
Wells Fargo & Company - Analyst

All right. I think we'll get started. My name is Derek Archila. I'm one of the senior biotech analysts here at Wells. I'm very excited to have our next company up here, Nurix Therapeutics. From the company, we have Arthur Sands, the CEO. So, Arthur, thanks for joining us.

Arthur Sands
Nurix Therapeutics, Inc. - President, CEO & Board Director

Thanks, Derek. Happy to be here.

Questions & Answers

Derek Archila
Wells Fargo & Company - Analyst

Awesome. Maybe just to start, give us a little bit of background about Nurix and what you guys are working on. You have a couple programs in development. So maybe just give a little bit of background on each.

Arthur Sands
Nurix Therapeutics, Inc. - President, CEO & Board Director

Sure. So we have four programs in Phase 1, and I'll be talking more about each of those, covering leukemia, lymphoma, and solid tumors. They all derive from a really exciting

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot